House Inquiry Into ImClone Could Lead To FDA Changes
By Kim Coghill
Tuesday, June 18, 2002
WASHINGTON - A congressional investigation into ImClone Systems Inc.'s handling of the cancer drug Erbitux eventually could end in a more transparent FDA. (BioWorld Today)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.